This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Gene-Edited Cell Therapies: CMC Challenges and Considerations - WHITEPAPER


Download the exclusive whitepaper

Gene-edited cell therapies showed potential as a treatment for many diseases, especially for blood-based cancer patients who do not respond to any other treatment. And presently, CAR T cells are increasingly being reprogrammed to express small molecules and drugs that can serve as an addition to existing therapies.

This whitepaper reviews the current challenges in manufacturing gene-edited cell therapies and steps to approach them, including:

  • Manufacturing challenges and protocols for gene-edited cell therapies

  • Considerations for allogeneic products, including CAR & T cell products

  • Current industry developments

  • Best practice strategies in maintaining safety/efficacy

  • Opportunities for automation/technological innovation

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.